Chiles Center, College of Public Health, University of South Florida, 13201 Bruce B. Downs Blvd, MDC56, Tampa, FL, 33612-3805, USA.
Florida Department of Health, Florida Birth Defects Registry, Tallahassee, USA.
Matern Child Health J. 2023 Dec;27(Suppl 1):44-51. doi: 10.1007/s10995-023-03669-6. Epub 2023 May 18.
Studies have shown significant increases in the prevalence of maternal opioid use. Most prevalence estimates are based on unverified ICD-10-CM diagnoses. This study determined the accuracy of ICD-10-CM opioid-related diagnosis codes documented during delivery and examined potential associations between maternal/hospital characteristics and diagnosis with an opioid-related code.
To identify people with prenatal opioid use, we identified a sample of infants born during 2017-2018 in Florida with a NAS related diagnosis code (P96.1) and confirmatory NAS characteristics (N = 460). Delivery records were scanned for opioid-related diagnoses and prenatal opioid use was confirmed through record review. The accuracy of each opioid-related code was measured using positive predictive value (PPV) and sensitivity. Modified Poisson regression was used to calculate adjusted relative risks (aRR) and 95% confidence intervals (CI).
We found the PPV was nearly 100% for all ICD-10-CM opioid-related codes (98.5-100%) and the sensitivity was 65.9%. Non-Hispanic Black mothers were 1.8 times more likely than non-Hispanic white mothers to have a missed opioid-related diagnosis at delivery (aRR:1.80, CI 1.14-2.84). Mothers who delivered at a teaching status hospital were less likely to have a missed opioid-related diagnosis (p < 0.05).
We observed high accuracy of maternal opioid-related diagnosis codes at delivery. However, our findings suggest that over 30% of mothers with opioid use may not be diagnosed with an opioid-related code at delivery, although their infant had a confirmed NAS diagnosis. This study provides information on the utility and accuracy of ICD-10-CM opioid-related codes at delivery among mothers of infants with NAS.
研究表明,产妇阿片类药物使用的患病率显著增加。大多数流行率估计值基于未经证实的 ICD-10-CM 诊断。本研究旨在确定分娩期间记录的 ICD-10-CM 阿片类药物相关诊断代码的准确性,并研究产妇/医院特征与阿片类药物相关代码诊断之间的潜在关联。
为了确定有产前阿片类药物使用史的人群,我们在佛罗里达州确定了一个在 2017-2018 年期间出生的患有与 NAS 相关诊断代码(P96.1)和确认性 NAS 特征的婴儿样本(N=460)。扫描分娩记录以确定阿片类药物相关诊断,通过记录审查确认产前阿片类药物使用情况。使用阳性预测值(PPV)和灵敏度来衡量每个阿片类药物相关代码的准确性。使用修正泊松回归计算调整后的相对风险(aRR)和 95%置信区间(CI)。
我们发现,所有 ICD-10-CM 阿片类药物相关代码的 PPV 接近 100%(98.5-100%),灵敏度为 65.9%。与非西班牙裔白人母亲相比,非西班牙裔黑人母亲在分娩时更有可能被漏诊阿片类药物相关诊断(aRR:1.80,CI 1.14-2.84)。在教学状态医院分娩的母亲不太可能被漏诊阿片类药物相关诊断(p<0.05)。
我们观察到分娩时产妇阿片类药物相关诊断代码的准确性很高。然而,我们的研究结果表明,尽管他们的婴儿有确诊的 NAS 诊断,但仍有超过 30%的阿片类药物使用者母亲在分娩时没有被诊断出阿片类药物相关代码。本研究提供了有关 ICD-10-CM 阿片类药物相关代码在 NAS 婴儿产妇分娩时的实用性和准确性的信息。